Serplulimab: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving Serplulimab

• A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy
  NCT07604909 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
  NCT07269782 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
  NCT06848699 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
  NCT07739758 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study
  NCT05954429 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
  NCT05766800 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
  NCT06497530 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
  NCT06781281 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer
  NCT06368141 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
  NCT06280495 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
  NCT07283692 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
  NCT06521866 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
  NCT06850103 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
  NCT05731726 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Serplulimab Combined With CCRT for LS-SCLC.
  NCT06295926 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
  NCT06860529 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%
  NCT07596121 · Phase: Phase 2 · Ages: 65 Years and older · Sex: All (male and female) · 1 location
• Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
  NCT07231445 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
  NCT07583511 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many recruiting trials involve Serplulimab?

19 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.